Compare FUNC & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUNC | MDWD |
|---|---|---|
| Founded | 1900 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.8M | 230.7M |
| IPO Year | N/A | 2014 |
| Metric | FUNC | MDWD |
|---|---|---|
| Price | $38.62 | $17.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | 16.7K | ★ 67.9K |
| Earning Date | 10-20-2025 | 11-20-2025 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | ★ 56.67 | N/A |
| EPS | ★ 3.84 | N/A |
| Revenue | ★ $83,662,000.00 | $20,932,000.00 |
| Revenue This Year | $16.22 | $15.89 |
| Revenue Next Year | $7.42 | $25.33 |
| P/E Ratio | $9.94 | ★ N/A |
| Revenue Growth | ★ 17.79 | 6.15 |
| 52 Week Low | $24.66 | $14.14 |
| 52 Week High | $42.50 | $22.51 |
| Indicator | FUNC | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 47.68 |
| Support Level | $37.74 | $17.10 |
| Resistance Level | $38.69 | $18.40 |
| Average True Range (ATR) | 0.73 | 0.73 |
| MACD | 0.26 | -0.04 |
| Stochastic Oscillator | 95.72 | 46.67 |
First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.